Published in Br J Clin Pharmacol on May 01, 2015
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.02
The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag (2015) 0.84
The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery. Expert Rev Hematol (2013) 0.84
Spontaneous rectus sheath hematoma in a patient treated with apixaban. Intractable Rare Dis Res (2016) 0.81
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug Healthc Patient Saf (2016) 0.75
New oral anticoagulants for stroke prevention in atrial fibrillation: more choices bring more challenges. Hosp Pharm (2013) 0.75
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol (2017) 0.75
2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. J Arrhythm (2017) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.94
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther (1994) 5.22
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Clinical importance of the cytochromes P450. Lancet (2002) 3.77
The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos (2003) 3.33
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Grapefruit juice-drug interactions. Br J Clin Pharmacol (1998) 2.68
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos (2008) 2.45
The human intestinal cytochrome P450 "pie". Drug Metab Dispos (2006) 2.31
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther (1994) 2.01
Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem (1987) 1.99
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos (2002) 1.92
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther (2000) 1.89
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov (2007) 1.63
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 1.40
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost (2008) 1.38
St John's Wort: effect on CYP3A4 activity. Clin Pharmacol Ther (2000) 1.30
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos (2009) 1.26
Warfarin and phenytoin interaction. Ann Intern Med (1979) 1.26
Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet (1988) 1.20
Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance. Eur J Clin Pharmacol (1992) 1.11
Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther (1999) 1.02
Comparison of midazolam and simvastatin as cytochrome P450 3A probes. Clin Pharmacol Ther (2006) 1.00
The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev (2001) 0.98
Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol (2009) 0.96
Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos (2009) 0.95
Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos (2013) 0.90
Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos (2010) 0.90
Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos (2009) 0.90
Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem (2000) 0.89
Factor Xa--a promising target for drug development. Cell Mol Life Sci (2002) 0.84
LC-MS/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis (2014) 0.79
Pharmacokinetics of a novel diltiazem HCl extended-release tablet formulation for evening administration. J Clin Pharmacol (2003) 0.78
Potentiation of warfarin action by miconazole oral gel. Aust N Z J Med (1991) 0.77
MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med (2012) 2.61
Built and social environments associations with adolescent overweight and activity. Am J Prev Med (2006) 2.55
Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med (2014) 2.53
Essential Staphylococcus aureus toxin export system. Nat Med (2013) 2.50
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos (2008) 2.45
Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. Proc Natl Acad Sci U S A (2007) 1.71
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69
Preliminary results of acoustic radiation force impulse (ARFI) ultrasound imaging of breast lesions. Ultrasound Med Biol (2011) 1.60
Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice. Proc Natl Acad Sci U S A (2004) 1.56
Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes Dev (2013) 1.54
What neighborhood area captures built environment features related to adolescent physical activity? Health Place (2010) 1.47
E(nos)/CG4699 required for nanos function in the female germ line of Drosophila. Genesis (2010) 1.47
CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum Mol Genet (2008) 1.43
CAS P8 -652 6N del polymorphism and breast cancer risk: a systematic review and meta-analysis. Neth J Med (2014) 1.40
Built and socioeconomic environments: patterning and associations with physical activity in U.S. adolescents. Int J Behav Nutr Phys Act (2010) 1.39
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol (2013) 1.39
Thyroid carcinoma in the McCune-Albright syndrome: contributory role of activating Gs alpha mutations. J Clin Endocrinol Metab (2003) 1.36
In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos (2009) 1.26
A comparison of four sampling methods among men having sex with men in China: implications for HIV/STD surveillance and prevention. AIDS Care (2011) 1.26
Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano (2010) 1.25
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos (2005) 1.22
Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol (2009) 1.22
Distribution of phytoplankton in the Three-Gorge Reservoir during rainy and dry seasons. Sci Total Environ (2006) 1.21
A role for Tbx5 in proepicardial cell migration during cardiogenesis. Physiol Genomics (2004) 1.21
A versatile family of degradable non-viral gene carriers based on hyperbranched poly(ester amine)s. J Control Release (2005) 1.16
Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data. Drug Metab Dispos (2006) 1.15
Decreased expression of microRNA-206 in breast cancer and its association with disease characteristics and patient survival. J Int Med Res (2013) 1.13
Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs (2014) 1.13
Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban--an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.12
Bisexual behavior among Chinese young migrant men who have sex with men: implications for HIV prevention and intervention. AIDS Care (2011) 1.10
Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol (2013) 1.05
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia. Immunology (2013) 1.04
Clinical pharmacokinetics of pregabalin in healthy volunteers. J Clin Pharmacol (2010) 1.04
Abnormal functional connectivity between the anterior cingulate and the default mode network in drug-naïve boys with attention deficit hyperactivity disorder. Psychiatry Res (2012) 1.04
Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis (2011) 1.02
Microarray analysis of gene expression by skeletal muscle of three mouse models of Kennedy disease/spinal bulbar muscular atrophy. PLoS One (2010) 1.02
Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics. Drug Metab Dispos (2008) 1.01
Matrine inhibits proliferation and induces apoptosis of pancreatic cancer cells in vitro and in vivo. Biol Pharm Bull (2010) 1.01
Recovery of function in a myogenic mouse model of spinal bulbar muscular atrophy. Neurobiol Dis (2008) 1.01
Longitudinal associations between neighborhood-level street network with walking, bicycling, and jogging: the CARDIA study. Health Place (2010) 1.01
Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry. J Mass Spectrom (2009) 1.00
The unfolded protein response modulates toxicity of the expanded glutamine androgen receptor. J Biol Chem (2005) 0.99
Almond consumption reduces oxidative DNA damage and lipid peroxidation in male smokers. J Nutr (2007) 0.98
Disrupting SUMOylation enhances transcriptional function and ameliorates polyglutamine androgen receptor-mediated disease. J Clin Invest (2015) 0.98
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost (2012) 0.97
Prevalence of cardiovascular disease and risk factors in a rural district of Beijing, China: a population-based survey of 58,308 residents. BMC Public Health (2012) 0.97
VEGF-induced angiogenesis ameliorates the memory impairment in APP transgenic mouse model of Alzheimer's disease. Biochem Biophys Res Commun (2011) 0.96
A Plasmodium-encoded cytokine suppresses T-cell immunity during malaria. Proc Natl Acad Sci U S A (2012) 0.94
Gender differences in the use of health care in China: cross-sectional analysis. Int J Equity Health (2014) 0.94
Cigarette smoking cessation and total and cause-specific mortality: a 22-year follow-up study among US male physicians. Arch Intern Med (2011) 0.94
Plankton community composition in the Three Gorges Reservoir Region revealed by PCR-dGGE and its relationships with environmental factors. J Environ Sci (China) (2008) 0.94
Randomized and controlled clinical study of modified prescriptions of Simiao Pill in the treatment of acute gouty arthritis. Chin J Integr Med (2008) 0.93
Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncol Rep (2011) 0.93
Assessment of the genotoxicity of endosulfan in earthworm and white clover plants using the comet assay. Arch Environ Contam Toxicol (2009) 0.92
A dynamic random access memory based on a conjugated copolymer containing electron-donor and -acceptor moieties. Angew Chem Int Ed Engl (2006) 0.92
A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses. J Mass Spectrom (2003) 0.92
Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther (2002) 0.91
ERP P1-N1 changes associated with Vernier perceptual learning and its location specificity and transfer. J Vis (2013) 0.91
Adventitial perfusion and intraplaque hemorrhage: a dynamic contrast-enhanced MRI study in the carotid artery. Stroke (2013) 0.91
Formulation of solid dosage forms to overcome gastric pH interaction of the factor Xa inhibitor, BMS-561389. Pharm Res (2006) 0.91
Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans. AAPS J (2011) 0.91
Quantification of 4-beta-hydroxycholesterol in human plasma using automated sample preparation and LC-ESI-MS/MS analysis. Chem Res Toxicol (2011) 0.90
Sulfation of o-demethyl apixaban: enzyme identification and species comparison. Drug Metab Dispos (2009) 0.90
p16INK4A immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: a prospective study in China. Int J Cancer (2013) 0.90
Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos (2010) 0.90
Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes. Drug Metab Dispos (2005) 0.90
Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet (2011) 0.89
Cucumis melo microRNA expression profile during aphid herbivory in a resistant and susceptible interaction. Mol Plant Microbe Interact (2012) 0.89
Molecular analysis of Staphylococcus epidermidis strains isolated from community and hospital environments in China. PLoS One (2013) 0.89
Microbial transformation of ginsenoside Rb(1) by Acremonium strictum. Appl Microbiol Biotechnol (2007) 0.89
A functional variant in the 3'-UTR of angiopoietin-1 might reduce stroke risk by interfering with the binding efficiency of microRNA 211. Hum Mol Genet (2010) 0.89
S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial. Medicine (Baltimore) (2015) 0.89
Longitudinal trends in gasoline price and physical activity: the CARDIA study. Prev Med (2011) 0.89
Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol (2006) 0.88
Breviscapine alleviates hepatic injury and inhibits PKC-mRNA and its protein expression in brain-dead BA-Ma mini pigs. Hepatobiliary Pancreat Dis Int (2007) 0.88
Alpha-adducin gene polymorphism is associated with essential hypertension in Chinese: a case-control and family-based study. J Hypertens (2003) 0.88
rAAV-mediated delivery of brain-derived neurotrophic factor promotes neurite outgrowth and protects neurodegeneration in focal ischemic model. Int J Clin Exp Pathol (2011) 0.88
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther (2014) 0.88
Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection. Rapid Commun Mass Spectrom (2008) 0.88
Diagnosis and treatment of lingual thyroglossal duct cyst in newborns. Pediatr Int (2009) 0.87
Prenatal flutamide enhances survival in a myogenic mouse model of spinal bulbar muscular atrophy. Neurodegener Dis (2010) 0.87
The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development. Clin Cancer Res (2008) 0.87
Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral. Int J Cancer (2010) 0.87
Nonvolatile polymer memory device based on bistable electrical switching in a thin film of poly(N-vinylcarbazole) with covalently bonded C60. Langmuir (2007) 0.87
Reporting guidelines for population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn (2015) 0.86